Trial Profile
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Upadacitinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALINA
- Sponsors Chugai Pharmaceutical; Roche
- 24 Oct 2023 Results from the prespecified interim analysis (At data cutoff 26 June 2023) assessing the efficacy and safety of adjuvant alectinib versus chemotherapy in patients with non-small cell lung cancer, presented at the 48th European Society for Medical Oncology Congress.
- 18 Oct 2023 Results published in the Genentech Media Release
- 18 Oct 2023 According to a Roche Media Release, full results of ALINA trial will be presented at the European Society of Medical Oncology (ESMO) Congress 2023 Presidential Symposium on Saturday 21 October 2023.